City of Hope (T Cell Manufacturing)

Duarte, CA
Find alternatives to City of Hope (T Cell Manufacturing) for CAR-T →
National Center
215 confirmed programs · 136 sponsors · Last scored 2026-11-02
84.0
Signal Score
✓ FDA Inspections (3) ✓ Clinical Trials (215) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: City of Hope (T Cell Manufacturing)

Signal Score
84.0/100 (as of 2026-11-02)
Quality Compliance
97.3/100
Headquarters
Duarte, CA
Modalities
CAR-T, Cell Therapy
Active Programs
215 confirmed from ClinicalTrials.gov across 136 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About City of Hope (T Cell Manufacturing)

CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 97.3
FDA Inspections3 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-08-20)
Operations 98.9
215 active programs across 136 sponsors
Modalities: CAR-T, Cell Therapy
131 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
215 active programs across 136 sponsors · Modalities: CAR-T, Cell Therapy · 131 programs in advanced phases (Phase 2/3)
Programs 215
Sponsors136
ModalitiesCAR-T, Cell Therapy
215 active programs across 136 sponsors
Modalities: CAR-T, Cell Therapy
131 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07711327 Atrial Fibrillation Among Patients With Hematologic... NA Not Yet Recruiting
NCT07702578 A Study of T-Cell Receptor Engineered Donor T Cells in... PHASE3 Recruiting
NCT07227155 The HOPE Biobank Resource (BMT CTN 2402 HOPE) NA Recruiting
NCT02943642 Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion... PHASE2 Withdrawn
NCT07544589 A Phase 1 Study Evaluating DISP-10 in Participants With... PHASE1 Recruiting
NCT07387367 A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment... PHASE3 Recruiting
NCT07227415 Symbiotic-GU-08: A Study to Learn About the Medicine Called... PHASE1/PHASE2 Recruiting
NCT07219212 A Study of JNJ-90301900 in Combination With Chemoradiation... PHASE1 Recruiting
NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients... PHASE1/PHASE2 Active Not Recruiting
NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the... PHASE1 Recruiting
View all 215 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 68.0
Parent company: City of Hope
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: City of Hope
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Duarte, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Duarte, CA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Duarte, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100

City of Hope (T Cell Manufacturing) FDA Inspection History

2025-08
2025-02
2024-12
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-08-20
Beckman Research Institute, City of Hope
Duarte, California Company-level
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2025-02-07
City Of Hope National Medical Center
Duarte, California Facility-linked
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
2024-12-09
City of Hope National Medical Center
Irvine, California Facility-linked
Blood and Blood Products Not posted No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

City of Hope (T Cell Manufacturing) FDA 483 Findings 3 observations · 2025-08-20 → 2025-08-20 ?

By subsystem

  • Laboratory Controls 2 (66.7%)
  • Documentation & Records 1 (33.3%)

By severity

  • 3 — Moderate: 2
  • 2 — Minor: 1
  • Repeat observations: 0

Most severe findings

  • Moderate (3) Laboratory Controls 2025-08-20 21 CFR 211.194(a)(2)
    Suitability of testing methods verified

    "The suitability of all testing methods is not verified under actual conditions of use."

  • Moderate (3) Laboratory Controls 2025-08-20 21 CFR 211.160(b)
    Scientifically sound laboratory controls

    "Laboratory controls do not include the establishment of scientifically sound and appropriate standards designed to assure that components conform to appropriate standards of identity, strength, quality and purity."

  • Minor (2) Documentation & Records 2025-08-20 21 CFR 211.22(d)
    Procedures not in writing, fully followed

    "The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed."

Clinical Activity 215 studies

NCT07711327 Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine... NA Not Yet Recruiting NCT07702578 A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing... PHASE3 Recruiting NCT07227155 The HOPE Biobank Resource (BMT CTN 2402 HOPE) NA Recruiting NCT02943642 Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in... PHASE2 Withdrawn NCT07544589 A Phase 1 Study Evaluating DISP-10 in Participants With Advanced... PHASE1 Recruiting NCT07387367 A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus... PHASE3 Recruiting NCT07227415 Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404... PHASE1/PHASE2 Recruiting NCT07219212 A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in... PHASE1 Recruiting NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration... PHASE1/PHASE2 Active Not Recruiting NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of... PHASE1 Recruiting NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of... PHASE1 Recruiting NCT06976736 A Long Term Follow-up Study of TScan TCR-T Products NA Recruiting NCT06859424 A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based... PHASE2 Recruiting NCT07075185 A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and... PHASE1 Recruiting NCT07038447 A Study of KITE-363 in Participants With Refractory Autoimmune Diseases PHASE1 Enrolling By Invitation NCT06552416 Safety of MT-401-OTS in Patients With Relapsed AML or MDS PHASE1 Recruiting NCT06533579 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) PHASE1/PHASE2 Recruiting NCT06657144 A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other... PHASE1 Recruiting NCT06805305 DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult... PHASE2 Recruiting NCT06528301 A Phase 1 Study of UB-VV111 With and Without Rapamycin in... PHASE1 Recruiting
+ 195 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data. This company's careers site asks automated readers not to collect it (robots.txt), and we respect that.
Source: public careers pages · Checked Nov 20, 2026

Frequently Asked Questions About City of Hope (T Cell Manufacturing)

How many FDA inspections does City of Hope (T Cell Manufacturing) have on record?
CDMO Signal tracks 3 FDA inspections for City of Hope (T Cell Manufacturing), sourced from the FDA inspection database. See the full inspection history above.
Has City of Hope (T Cell Manufacturing) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for City of Hope (T Cell Manufacturing).
How many clinical programs is City of Hope (T Cell Manufacturing) linked to?
City of Hope (T Cell Manufacturing) is associated with 215 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is City of Hope (T Cell Manufacturing)'s CDMO Signal Score?
City of Hope (T Cell Manufacturing) has a Signal Score of 84/100, based on quality, operations, financial stability, and capacity data.
Evaluating City of Hope (T Cell Manufacturing) for a manufacturing program?
Use the free AI matchmaker to compare City of Hope (T Cell Manufacturing) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Cellares
South San Francisco, CA
Signal Score: 59.0
CAR-T, Cell Therapy
Poseida Therapeutics (CDMO)
San Diego, CA
Signal Score: 58.7
CAR-T, Cell Therapy, Gene Editing
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy

Compare City of Hope (T Cell Manufacturing) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on City of Hope (T Cell Manufacturing)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.